Literature DB >> 24328853

Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia?

Roberto Cangemi1, Camilla Calvieri, Tommaso Bucci, Roberto Carnevale, Marco Casciaro, Elisabetta Rossi, Cinzia Myriam Calabrese, Gloria Taliani, Stefania Grieco, Marco Falcone, Paolo Palange, Giuliano Bertazzoni, Andrea Celestini, Pasquale Pignatelli, Francesco Violi.   

Abstract

In the present study, we tested the hypothesis that oxidative stress could be implicated in myocardial damage during the acute phase of pneumonia. NOX2 activation, the catalytic subunit of NADPH oxidase, and high-sensitivity cardiac troponin T (hs-cTnT) elevation have been analyzed in two hundred forty-eight consecutive patients hospitalized for community-acquired pneumonia. Serum NOX2-derived peptide (sNOX2-dp), a marker of NOX2 activation, and 8-isoprostaglandin F2α (8-iso-PGF2α), a marker of oxidative stress, were measured upon admission; serum hs-cTnT and ECG were measured every 12 and 24 h, respectively. One hundred thirty-five patients (54%) showed elevated serum levels of hs-cTnT (>0.014 μg/L). A logistic regression analysis showed sNOX2-dp (p<0.001), Pneumonia Severity Index score (p<0.001), renal failure (p=0.024), and ejection fraction (p<0.001) as independent predictors of elevated serum levels of hs-cTnT. Serum sNOX2-dp was linearly correlated with hs-cTnT (Rs=0.538; p<0.001) and 8-iso-PGF2α (Rs=0.354; p<0.001). The study provides the first evidence of a significant association between serum cardiac Troponin T elevation and NOX2 upregulation in patients with pneumonia. This finding raises the hypothesis that NOX2-derived oxidative stress may be implicated in myocardial injury and that its inhibition could be a novel therapeutic strategy to limit it.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24328853      PMCID: PMC4038979          DOI: 10.1089/ars.2013.5766

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  9 in total

1.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 2.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard A Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michael Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

Review 4.  Acute pneumonia and the cardiovascular system.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; Svetlana Shachkina; Julio A Chirinos
Journal:  Lancet       Date:  2013-01-16       Impact factor: 79.321

Review 5.  Oxidative and nitrosative stress in the maintenance of myocardial function.

Authors:  Yixuan Zhang; Carlo G Tocchetti; Thomas Krieg; An L Moens
Journal:  Free Radic Biol Med       Date:  2012-07-20       Impact factor: 7.376

6.  Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; George A Wells; Julio A Chirinos; Li Chen; Michael J Fine
Journal:  Circulation       Date:  2012-01-04       Impact factor: 29.690

7.  Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia.

Authors:  Pasquale Pignatelli; Roberto Carnevale; Roberto Cangemi; Lorenzo Loffredo; Valerio Sanguigni; Claudio Stefanutti; Stefania Basili; Francesco Violi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

8.  Effect of statin treatment on short term mortality after pneumonia episode: cohort study.

Authors:  Ian Douglas; Stephen Evans; Liam Smeeth
Journal:  BMJ       Date:  2011-04-06

9.  Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults.

Authors:  Catherina L Chang; Graham D Mills; Noel C Karalus; Lance C Jennings; Richard Laing; David R Murdoch; Stephen T Chambers; Dominic Vettise; Christine M Tuffery; Robert J Hancox
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  9 in total
  8 in total

1.  Serum NOX2 as a new biomarker candidate for HBV-related disorders.

Authors:  Yuan Xiong; Yuanyuan Ye; Pu Li; Yahui Xiong; Jinju Mao; Yong Huang; Weixian Chen; Bo Wang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 2.  Do Diet and Dietary Supplements Mitigate Clinical Outcomes in COVID-19?

Authors:  Bhavdeep Singh; Eli Eshaghian; Judith Chuang; Mihai Covasa
Journal:  Nutrients       Date:  2022-05-02       Impact factor: 6.706

3.  Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin.

Authors:  Marco Falcone; Alessandro Russo; Roberto Cangemi; Alessio Farcomeni; Camilla Calvieri; Francesco Barillà; Maria Gabriella Scarpellini; Giuliano Bertazzoni; Paolo Palange; Gloria Taliani; Mario Venditti; Francesco Violi
Journal:  J Am Heart Assoc       Date:  2015-01-06       Impact factor: 5.501

4.  Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial.

Authors:  Francesco Violi; Camilla Calvieri; Roberto Cangemi
Journal:  Intern Emerg Med       Date:  2019-05-31       Impact factor: 3.397

5.  Impact of Cardiovascular Diseases on COVID-19: A Systematic Review.

Authors:  Qingtai Cao; HanYu Lei; MengLing Yang; Le Wei; YinMiao Dong; JiaHao Xu; Mi Nasser; MengQi Liu; Ping Zhu; LinYong Xu; MingYi Zhao
Journal:  Med Sci Monit       Date:  2021-04-06

6.  Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes: Results From a Prospective Cohort Study.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Russo; Laura Giordo; Elisa Manzini; Giuliano Bertazzoni; Paolo Palange; Gloria Taliani; Roberto Cangemi; Alessio Farcomeni; Vincenzo Vullo; Francesco Violi; Mario Venditti
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 7.  SARS-CoV-2 and myocardial injury: a role for Nox2?

Authors:  Francesco Violi; Daniele Pastori; Pasquale Pignatelli; Roberto Cangemi
Journal:  Intern Emerg Med       Date:  2020-05-12       Impact factor: 3.397

8.  Interplay between Nox2 Activity and Platelet Activation in Patients with Sepsis and Septic Shock: A Prospective Study.

Authors:  Giusy Tiseo; Elena Cavarretta; Arianna Forniti; Cristina Nocella; Sebastiano Sciarretta; Ornella Spagnolello; Enrico Baldini; Mariangela Peruzzi; Giuliano Bertazzoni; Francesco Menichetti; Antonino G M Marullo; Fabio Miraldi; Andrea Morelli; Giacomo Frati; Roberto Carnevale; Falcone Marco
Journal:  Oxid Med Cell Longev       Date:  2020-10-27       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.